Drug Approval | May 31, 2021
Cadila Healthcare’s margin supported by lower R&D : ICICI Securities
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
The IPO comprises a fresh issue of up to Rs. 11,600 million and an offer for sale of up to 7,305,245 equity shares of Rs. 2 each of Glenmark Life Sciences by Glenmark Pharmaceuticals
GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
PEL will explore the PLI scheme and apply if its beneficial.
The company will be holding 26% of the share capital in each of the solar power generating companies.
Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.
Subscribe To Our Newsletter & Stay Updated
